Adjuvant Chemotherapy Necessity in Stage I Ovarian Endometrioid Carcinoma: A SEER-Based Study Verified by Single-Center Data and Meta-Analysis.

IF 4.1 4区医学 Q3 ONCOLOGY

Oncology Research Pub Date : 2025-09-26 eCollection Date: 2025-01-01 DOI:10.32604/or.2025.065137

Liang Yu, Mingrui Zhao, Jinhui Liu, Yuqin Yang, Lin Zhang, Wenjun Cheng

{"title":"Adjuvant Chemotherapy Necessity in Stage I Ovarian Endometrioid Carcinoma: A SEER-Based Study Verified by Single-Center Data and Meta-Analysis.","authors":"Liang Yu, Mingrui Zhao, Jinhui Liu, Yuqin Yang, Lin Zhang, Wenjun Cheng","doi":"10.32604/or.2025.065137","DOIUrl":null,"url":null,"abstract":"Background: The benefit of adjuvant chemotherapy for stage I ovarian endometrioid carcinoma (OEC) remains controversial. Hence, the study sought to explore its value in stage I OEC patients.Methods: Stage I OEC patients (1988-2018) were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Multivariate Cox analysis was used to control confounders. Logistic regression was used to explore factors associated with adjuvant chemotherapy. Cox regression analysis and Kaplan-Meier curves were used to assess the survival benefits. Single-center clinical data and meta-analysis following PRISMA guidelines provided external validation.Result: Adjuvant chemotherapy correlated with improved survival (Hazard Ratio (HR): 0.860, p = 0.011), as did lymphadenectomy (HR: 0.842, p < 0.001). Higher age, pathological stage, and tumor grade negatively affected survival. Chemotherapy administration associated with higher pathological stage (IB: Odds Ratio (OR) 1.565, p < 0.001; IC: OR 4.091, p < 0.001), higher grade (G2: OR 2.336, p < 0.001; G3: OR 4.563, p < 0.001), and lymphadenectomy (OR 1.148, p = 0.040). Stratification analysis showed adjuvant chemotherapy failed to improve prognosis in stage IA/IB patients regardless of grade or lymphadenectomy. For stage IC patients, chemotherapy benefited grade 1-2 or grade 3 patients without lymphadenectomy, and grade 3 patients with lymphadenectomy. Meta-analysis revealed reduced recurrence in stage IC patients (OR = 0.50, p = 0.035).Conclusion: Adjuvant chemotherapy confers survival benefits for stage IC patients, particularly those without lymphadenectomy.","PeriodicalId":19537,"journal":{"name":"Oncology Research","volume":"33 10","pages":"3007-3022"},"PeriodicalIF":4.1000,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12493988/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.32604/or.2025.065137","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The benefit of adjuvant chemotherapy for stage I ovarian endometrioid carcinoma (OEC) remains controversial. Hence, the study sought to explore its value in stage I OEC patients.

Methods: Stage I OEC patients (1988-2018) were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Multivariate Cox analysis was used to control confounders. Logistic regression was used to explore factors associated with adjuvant chemotherapy. Cox regression analysis and Kaplan-Meier curves were used to assess the survival benefits. Single-center clinical data and meta-analysis following PRISMA guidelines provided external validation.

Result: Adjuvant chemotherapy correlated with improved survival (Hazard Ratio (HR): 0.860, p = 0.011), as did lymphadenectomy (HR: 0.842, p < 0.001). Higher age, pathological stage, and tumor grade negatively affected survival. Chemotherapy administration associated with higher pathological stage (IB: Odds Ratio (OR) 1.565, p < 0.001; IC: OR 4.091, p < 0.001), higher grade (G2: OR 2.336, p < 0.001; G3: OR 4.563, p < 0.001), and lymphadenectomy (OR 1.148, p = 0.040). Stratification analysis showed adjuvant chemotherapy failed to improve prognosis in stage IA/IB patients regardless of grade or lymphadenectomy. For stage IC patients, chemotherapy benefited grade 1-2 or grade 3 patients without lymphadenectomy, and grade 3 patients with lymphadenectomy. Meta-analysis revealed reduced recurrence in stage IC patients (OR = 0.50, p = 0.035).

Conclusion: Adjuvant chemotherapy confers survival benefits for stage IC patients, particularly those without lymphadenectomy.

查看原文本刊更多论文

一期卵巢子宫内膜样癌的辅助化疗必要性：单中心数据和荟萃分析验证的基于seer的研究

背景：辅助化疗对I期卵巢子宫内膜样癌（OEC）的益处仍有争议。因此，本研究试图探索其在I期OEC患者中的价值。方法：从监测、流行病学和最终结果（SEER）数据库中确定I期OEC患者（1988-2018）。采用多变量Cox分析控制混杂因素。采用Logistic回归分析辅助化疗的相关因素。采用Cox回归分析和Kaplan-Meier曲线评估生存获益。遵循PRISMA指南的单中心临床数据和荟萃分析提供了外部验证。结果：辅助化疗与生存率提高相关（风险比（HR）： 0.860, p = 0.011），淋巴结切除术与生存率提高相关（HR: 0.842, p < 0.001）。较高的年龄、病理分期和肿瘤分级对生存率有负面影响。化疗给药与较高病理分期相关(IB：优势比（OR） 1.565, p < 0.001；IC: OR 4.091, p < 0.001)、更高级别（G2: OR 2.336, p < 0.001; G3: OR 4.563, p < 0.001）和淋巴结切除术（OR 1.148, p = 0.040）。分层分析显示，辅助化疗未能改善IA/IB期患者的预后，与分级或淋巴结切除术无关。对于IC期患者，化疗使未行淋巴结切除术的1-2级或3级患者和行淋巴结切除术的3级患者受益。荟萃分析显示IC期患者的复发率降低（OR = 0.50, p = 0.035）。结论：辅助化疗可提高IC期患者的生存率，特别是那些未行淋巴结切除术的患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncology Research 医学-肿瘤学

CiteScore

4.40

自引率

0.00%

发文量

审稿时长

3 months

期刊介绍： Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.